Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS AND VIEWS

Antitumour T cells stand the test of time

Enhancing antitumour immune responses has revolutionized cancer treatment, yet some hurdles impede this approach. The discovery of a way to boost the lifespan and function of antitumour immune cells removes a key obstacle.
  1. Miguel Reina-Campos

    1. Miguel Reina-Campos is in the Division of Biological Sciences, University of California, San Diego, La Jolla, California 92093, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Ananda W. Goldrath

    1. Ananda W. Goldrath is in the Division of Biological Sciences, University of California, San Diego, La Jolla, California 92093, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Immune cells called cytotoxic CD8 T cells can directly kill tumours and are key weapons mobilized in many immunotherapy approaches used in the clinic. However, the cells’ activity can be thwarted by the ability of tumours to create harsh microenvironments, recruit immunoregulatory cells and induce inhibitory signals that hamper T-cell function, accumulation and tumour infiltration. Writing in Nature, Wei et al.1 report that depletion of the protein REGNASE-1 extends the survival of antitumour CD8 T cells and enhances their function, enabling the cells to fight cancer more effectively.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Nature 576, 392-393 (2019)

doi: https://doi.org/10.1038/d41586-019-03731-w

References

  1. Wei, J. et al. Nature 576, 471–476 (2019).

    Article  Google Scholar 

  2. Lim, W. A. & June, C. H. Cell 168, 724–740 (2017).

    Article  Google Scholar 

  3. Henning, A. N., Roychoudhuri, R. & Restifo, N. P. Nature Rev. Immunol. 18, 340–356 (2018).

    Article  Google Scholar 

  4. Zhang, L. & Romero, P. Trends Mol. Med. 24, 30–48 (2018).

    Article  Google Scholar 

  5. Matsushita, K. et al. Nature 458, 1185–1190 (2009).

    Article  Google Scholar 

  6. Iwasaki, H. et al. Nature Immunol. 12, 1167–1175 (2011).

    Article  Google Scholar 

  7. Uehata, T. et al. Cell 153, 1036–1049 (2013).

    Article  Google Scholar 

  8. Scharping, N. E. et al. Immunity 45, 701–703 (2016).

    Article  Google Scholar 

  9. Kurachi, M. et al. Nature Immunol. 15, 373–383 (2014).

    Article  Google Scholar 

  10. Miller, B. C. et al. Nature Immunol. 20, 326–336 (2019).

    Article  Google Scholar 

  11. Manguso, R. T. et al. Nature 547, 413–418 (2017).

    Article  Google Scholar 

Download references

Competing Interests

A.W.G. is on the SAB of Pandion Therapeutics and Arsenal Bio.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links